Colorectal cancer (CRC) cells often express
Tn antigen, a
tumor-associated truncated immature O-
glycan (GalNAcĪ±-O-Ser/Thr) that can promote
tumor progression.
Immunotherapies against
Tn antigen have been developed and are being evaluated in clinical trials.
Tn antigen can also be considered a novel immune checkpoint that induces immunosuppressive signaling through
glycan-biding
lectins to lead effector T cell apoptosis. We evaluated the correlation of
Tn antigen expression by immunohistochemistry with mismatch-repair (MMR) status, tumor-infiltrating lymphocytes,
tumor cell PD-L1 expression, and clinicopathological characteristics in 507 CRC patients. Although 91.9% of
CRCs showed negative or weak
Tn antigen staining (Tn-negative/weak), we identified a small subset of
CRCs (8.1%) that displayed particularly intense and diffuse distribution of
Tn antigen immunoreactivity (Tn-strong) that closely related to deficient MMR (dMMR). Moreover, 40 dMMR
CRCs were stratified into 24 Tn-negative/weak dMMR
tumors (60.0%) exhibiting dense CD8+ lymphocyte infiltrate concomitant with a high rate of PD-L1 positivity, and 16 Tn-strong dMMR
tumors (40.0%) that demonstrated CD8+ T cell exclusion and a lack of PD-L1 expression, which was comparable to those of proficient MMR. Our finding suggests that the immune cold subset of patients with Tn-strong dMMR CRC may be effectively treated with
immune checkpoint blockade therapy or cellular
immunotherapy targeting
Tn antigen.